Reliable assessment of BRCA1 and BRCA2 germline variants by next-generation sequencing: a multicenter study.
BACKGROUND
BRCA1/2 gene mutation testing, based on next-generation sequencing (NGS), has been gradually applied in the clinic to serve as preventive early screening for predisposed individuals or to provide treatment options for patients with hereditary breast or ovarian cancers. Here, we evaluated the accuracy of NGS-based mutation detection in BRCA1/2 and the consistency in variant interpretation among clinical laboratories to find the possible reasons underlying inaccurate results and discrepant variant interpretation.


METHODS
Laboratories were asked to use their routine procedures to detect six mimetic DNA samples with different BRCA1/2 germline variants. The results of variant detection were required to be submitted via a web-based evaluation system and were automatically scored, according to predefined criteria. The variant interpretation report, including the detailed clinical evidence, was summarized and analyzed for reasons underlying inconsistent results.


RESULTS
Overall, only 55.2% (16/29) of laboratories, whose detection score was higher than 90 points, was found to be an acceptable detection capability level. 82.9% (29/35) of the errors were genotype errors. The variant classification results were generally consistent, and 77.8% (7/9) of the variants were given the consistent classification answer. Only two single nucleotide variants (SNVs) had a discrepant classification opinion across laboratories.


CONCLUSIONS
The BRCA1/2 variant detection performance should be further improved, especially in reporting the correct genome coordinates. Inconsistent variant classification may be a result of the different clinical pieces of evidence collected by the laboratories. However, discordant clinical evidence also appeared within the same classification results. Therefore, our study provided clear clinical evidence assessment strategies for BRCA1/2 variants, which was aimed at obtaining a consistent variant classification strategy for providing accurate clinical reports to the clinicians.
['Zhang|Rui|R|', 'Gao|Peng|P|', 'Han|Yanxi|Y|', 'Zhang|Runling|R|', 'Tan|Ping|P|', 'Zhou|Li|L|', 'Zhang|Jiawei|J|', 'Xie|Jiehong|J|', 'Li|Jinming|J|http://orcid.org/0000-0002-1476-3397']
D019313:BRCA1 Protein D024682:BRCA2 Protein D001943:Breast Neoplasms D005260:Female D018095:Germ-Line Mutation D059014:High-Throughput Nucleotide Sequencing D006801:Humans D008297:Male
Germline variant Next-generation sequencing BRCA1/2 Variant interpretation